

Reinhard Kirnbauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5071160/publications.pdf>

Version: 2024-02-01

22
papers

1,301
citations

623574

14
h-index

642610

23
g-index

23
all docs

23
docs citations

23
times ranked

1135
citing authors

#	ARTICLE	IF	CITATIONS
1	RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer. <i>Journal of Virology</i> , 2022, 96, .	1.5	9
2	Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists. <i>Vaccine</i> , 2021, 39, 292-302.	1.7	16
3	Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2748-2761.	1.4	11
4	RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates. <i>Journal of Clinical Medicine</i> , 2021, 10, 1044.	1.0	28
5	Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and in vivo potency with human papillomavirus VLPs-based vaccine. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 33, 102359.	1.7	13
6	Developments in L2-based human papillomavirus (HPV) vaccines. <i>Virus Research</i> , 2017, 231, 166-175.	1.1	61
7	Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). <i>PLoS ONE</i> , 2017, 12, e0169533.	1.1	43
8	Potential of a BPV1 L1 VLP vaccine to prevent BPV1- or BPV2-induced pseudo-sarcoid formation and safety and immunogenicity of EcPV2 L1 VLPs in horse. <i>Journal of General Virology</i> , 2017, 98, 230-241.	1.3	18
9	Type-specific L1 virus-like particle-mediated protection of horses from experimental bovine papillomavirus 1-induced pseudo-sarcoid formation is long-lasting. <i>Journal of General Virology</i> , 2017, 98, 1329-1333.	1.3	7
10	Establishment of an in vitro equine papillomavirus type 2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors. <i>Virology</i> , 2015, 486, 284-290.	1.1	11
11	A Chimeric 18L1-45RG1 Virus-Like Particle Vaccine Cross-Protects against Oncogenic Alpha-7 Human Papillomavirus Types. <i>PLoS ONE</i> , 2015, 10, e0120152.	1.1	29
12	Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach. <i>PLoS ONE</i> , 2015, 10, e0138722.	1.1	11
13	Impact of Inhibitors and L2 Antibodies upon the Infectivity of Diverse Alpha and Beta Human Papillomavirus Types. <i>PLoS ONE</i> , 2014, 9, e97232.	1.1	33
14	Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2706-2713.	0.3	77
15	Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation. <i>Journal of General Virology</i> , 2011, 92, 2437-2445.	1.3	42
16	Serological relationship between cutaneous human papillomavirus types 5, 8 and 92. <i>Journal of General Virology</i> , 2009, 90, 136-143.	1.3	12
17	Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. <i>Virology</i> , 2009, 393, 1-6.	1.1	28
18	Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines. <i>Journal of Virology</i> , 2009, 83, 10085-10095.	1.5	127

#	ARTICLE	IF	CITATIONS
19	Peripheral blood mononuclear cells represent a reservoir of bovine papillomavirus DNA in sarcoid-affected equines. <i>Journal of General Virology</i> , 2008, 89, 1390-1395.	1.3	81
20	Papillomavirus-Like Particles Are an Effective Platform for Amyloid- β Immunization in Rabbits and Transgenic Mice. <i>Journal of Immunology</i> , 2006, 177, 2662-2670.	0.4	52
21	Different Heparan Sulfate Proteoglycans Serve as Cellular Receptors for Human Papillomaviruses. <i>Journal of Virology</i> , 2003, 77, 13125-13135.	1.5	229
22	A Virus-Like Particle Enzyme-Linked Immunosorbent Assay Detects Serum Antibodies in a Majority of Women Infected With Human Papillomavirus Type 16. <i>Journal of the National Cancer Institute</i> , 1994, 86, 494-499.	3.0	362